Welcome Center  |   Log In  |   Register  |   Follow Us  Facebook  Twitter Google Plus

More in Dermatology

Staff reviewers at the FDA have confirmed that Novartis‘ new psoriasis drug, secukinumab, poses no major safety issues to patients. According to Reuters, secukinumab (AIN457) is expected to lead the way in immunosuppresant therapy, a class of drugs...
Merck & Co. Inc.’s immune-stimulating melanoma drug, Keytruda (pembrolizumab) has received FDA approval, a Reuters article says. The drug, which is designed to stimulate the immune system to fight off cancer by blocking PD-1 proteins, is the...
According to an article published by Reuters, Eli Lilly and Company has announced an improved experimental drug used to treat psoriasis. The drug, ixekizumab, proved to have significantly greater levels of skin clearance than current generic therapies or...